AtriCure cleared to try hybrid atrial fibrillation procedure

AtriCure, the maker of cardiac surgical ablation systems, has received a conditional nod from the FDA to evaluate the safety and efficacy of a hybrid procedure to treat patients with persistent forms of atrial fibrillation. Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.